Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

Cited by (1,078)

Items 701–800 of 1,078

1. Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma
   Morganstein, D.L., Lai, Z., Spain, L., Diem, S., Levine, D., Mace, C., Gore, M., Larkin, J. · 2017 · Clinical Endocrinology
2. Molecular approaches for classifying endometrial carcinoma
   Josep Maria Piulats, Esther Guerra, Marta Gil-Martín, Berta Roman‐Canal, Sónia Gatius, Rebeca Sanz Pamplona, Ana Velasco, August Vidal, Xavier Matías‐Guiu · 2016 · Gynecologic Oncology
3. Melanoma: What do all the mutations mean?
   Elizabeth J. Davis, Douglas Buckner Johnson, Jeffrey Alan Sosman, Sunandana Chandra · 2018 · Cancer
4. Responsiveness to anti-PD-1 and anti-CTLA-4 immune checkpoint blockade in SB28 and GL261 mouse glioma models
   Vassilis Genoud, Eliana Marinari, Sergey I. Nikolaev, John C. Castle, Valesca Bukur, Pierre‐Yves Dietrich, Hideho Okada, Paul R. Walker · 2018 · OncoImmunology
5. Neurologic complications of immune checkpoint inhibitors
   Alexandra M. Haugh, John C. Probasco, Douglas Buckner Johnson · 2020 · Expert Opinion on Drug Safety
6. Epigenetics and immunotherapy: The current state of play
   Jennifer Dunn, Sudha Rao · 2017 · Molecular Immunology
7. Immune checkpoint inhibitors and elderly people: A review
   Amaury Daste, Charlotte Domblides, Marine Gross‐Goupil, Camille Chakiba, Amandine Quivy, Valérie Cochin, Erwan de Monès, Nicolas Larmonier, Pierre Soubeyran, Alain Ravaud · 2017 · European Journal of Cancer
8. Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study
   Margaret K. Callahan, Harriet M. Kluger, Michael Andrew Postow, Neil Howard Segal, Alexander M. Lesokhin, Michael B. Atkins, John M. Kirkwood, Suba Krishnan, Rafia Bhore, Christine E. Horak et al. · 2017 · Journal of Clinical Oncology
9. Defining and Understanding Adaptive Resistance in Cancer Immunotherapy
   Tae Kon Kim, Roy S. Herbst, Lieping Chen · 2018 · Trends in Immunology
10. Are Conventional Type 1 Dendritic Cells Critical for Protective Antitumor Immunity and How?
    Jean-Charles Cancel, Karine Crozat, Marc Dalod, Raphaël Mattiuz · 2019 · Frontiers in Immunology
11. Long-Term Outcomes and Responses to Retreatment in Patients With Melanoma Treated With PD-1 Blockade
    Allison Betof Warner, Jessica S. Palmer, Alexander Noor Shoushtari, Debra A. Goldman, Katherine S. Panageas, Sara A. Hayes, Raazi Bajwa, Parisa Momtaz, Margaret K. Callahan, Jedd D. Wolchok et al. · 2020 · Journal of Clinical Oncology
12. Deletion of the inhibitory co-receptor CTLA-4 enhances and invigorates chimeric antigen receptor T cells
    Sangya Agarwal, Maria Angela Aznar, Andrew J. Rech, Charly Ryan Good, Shunichiro Kuramitsu, Tong Da, Mercy Gohil, Linhui Chen, Seok-Jae Albert Hong, Pranali Ravikumar et al. · 2023 · Immunity
13. Expression of PD-L1 and presence of CD8-positive T cells in pre-treatment specimens of locally advanced cervical cancer
    Emeka K. Enwere, Elizabeth N. Kornaga, Michelle Liane Dean, Theodora A. Koulis, Tien Phan, Maria Kalantarian, Martin Köbel, Prafull Ghatage, Anthony M. Magliocco, Susan P. Lees‐Miller et al. · 2017 · Modern Pathology
14. LAG-3+ tumor infiltrating lymphocytes in breast cancer: clinical correlates and association with PD-1/PD-L1+ tumors
    S Burugu, Dongxia Gao, Samuel C. Y. Leung, Stephen Chia, Torsten O. Nielsen · 2017 · Annals of Oncology
15. Biomarkers for immunotherapy in bladder cancer: a moving target
    David Henry Aggen, Charles G. Drake · 2017 · Journal for ImmunoTherapy of Cancer
16. Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination
    Jun Gong, Thang Q. Le, Erminia Massarelli, Andrew Eugene Hendifar, Richard Tuli · 2018 · Journal for ImmunoTherapy of Cancer
17. BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival
    Erinna F. Lee, Tiffany J. Harris, Sharon H. Tran, Marco Evangelista, Surein Arulananda, Thomas John, Celeste Ramnac, Chloe Hobbs, Haoran Zhu, Gency Ponrose Gunasingh et al. · 2019 · Cell Death and Disease
18. Blockade of LAG-3 and PD-1 leads to co-expression of cytotoxic and exhaustion gene modules in CD8+ T cells to promote antitumor immunity
    Anthony Richard Cillo, Carly Cardello, Feng Shan, Lilit Karapetyan, Sheryl R. Kunning, Cindy Sander, Elizabeth A. Rush, Arivarasan D. Karunamurthy, Ryan Campbell Massa, Anjali Rohatgi et al. · 2024 · Cell
19. Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors
    Hasan Ali, Omar, Berner, Fiamma, Bomze, David, Fässler, Mirjam, Diem, Stefan, Cozzio, Antonio, Jörger, Markus, Früh, Martin, Driessen, Christoph, Lenz, Tobias L. et al. · 2019 · European Journal of Cancer
20. Statistical determination of synergy based on Bliss definition of drugs independence
    Demidenko, Eugene, Miller, Todd W. · 2019 · PLOS ONE
21. Early Use of High-Dose Glucocorticoid for the Management of irAE Is Associated with Poorer Survival in Patients with Advanced Melanoma Treated with Anti–PD-1 Monotherapy
    Xue Li Bai, Jiani Hu, Allison Betof Warner, Henry T. Quach, Christopher Cann, Michael Z. Zhang, Lu Si, Bixia Tang, Chuanliang Cui, Xiaoling Yang et al. · 2021 · Clinical Cancer Research
22. Histopathologic Features of Colitis Due to Immunotherapy With Anti-PD-1 Antibodies
    Chen, Jonathan H., Pezhouh, Maryam K., Lauwers, Gregory Y., Masia, Ricard · 2017 · American Journal of Surgical Pathology
23. Design and Efficacy of a Monovalent Bispecific PD-1/CTLA4 Antibody That Enhances CTLA4 Blockade on PD-1+ Activated T Cells
    Dovedi, Simon J., Elder, Matthew J., Yang, Chunning, Sitnikova, Suzanne I., Irving, Lorraine, Hansen, Anna, Hair, James, Jones, Des C., Hasani, Sumati, Wang, Bo et al. · 2021 · Cancer Discovery
24. A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers
    Scott N. Gettinger, Jungmin Choi, Nikita Lavanya Mani, Miguel F. Sanmamed, Ila J. Datar, Ryan Sowell, Victor Y. Du, Edward J. Kaftan, Sarah B. Goldberg, Weilai Dong et al. · 2018 · Nature Communications
25. The Impact of Radiation Therapy on Lymphocyte Count and Survival in Metastatic Cancer Patients Receiving PD-1 Immune Checkpoint Inhibitors
    Luke Pike, Andrew Bang, Brandon Arvin Virgil Mahal, Allison Taylor, Monica Shalini Krishnan, Alexander Spektor, Daniel N. Cagney, Ayal Aaron Aizer, Brian Michael Alexander, Osama E. Rahma et al. · 2018 · International Journal of Radiation Oncology*Biology*Physics
26. Molecular Pathology of Skin Melanoma: Epidemiology, Differential Diagnostics, Prognosis and Therapy Prediction
    József Tı́már, Andrea Ladányi · 2022 · International Journal of Molecular Sciences
27. State of the science on prevention and screening to reduce melanoma incidence and mortality: The time is now
    Mary K. Tripp, Meg Watson, Sophie J. Balk, Susan M. Swetter, Jeffrey E. Gershenwald · 2016 · CA A Cancer Journal for Clinicians
28. Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL)
    on behalf of the European Conference on Infections in Leukemia (ECIL), Georg Maschmeyer, Julien De Greef, Sibylle C. Mellinghoff, Annamaria Nosari, Anne Thiébaut, Anne Bergeron, Tomás Franquet, Nicole M. A. Blijlevens, Johan A. Maertens · 2019 · Leukemia
29. Association of Anti-TNF with Decreased Survival in Steroid Refractory Ipilimumab and Anti-PD1–Treated Patients in the Dutch Melanoma Treatment Registry
    Rik Jasper Verheijden, Anne Maria May, Christian U. Blank, Maureen J.B. Aarts, Franchette W.P.J. van den Berkmortel, Alfons J.M. van den Eertwegh, Jan Willem B. de Groot, Marye J. Boers‐Sonderen, Jacobus J. M. van der Hoeven, Geke A.P. Hospers et al. · 2020 · Clinical Cancer Research
30. Immune checkpoint inhibitors: Key trials and an emerging role in breast cancer
    Nicola Gaynor, John Paul Crown, Denis Martin Collins · 2020 · Seminars in Cancer Biology
31. Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial
    Ari M. Vanderwalde, Shay L. Bellasea, Kari Lynn Kendra, Nikhil I. Khushalani, Katie Marie Campbell, Philip O. Scumpia, Lawrence F. Kuklinski, Frances A. Collichio, Jeffrey Alan Sosman, Alexandra P. Ikeguchi et al. · 2023 · Nature Medicine
32. Probody Therapeutics: An Emerging Class of Therapies Designed to Enhance On-Target Effects with Reduced Off-Tumor Toxicity for Use in Immuno-Oncology
    Karen A. Autio, Valentina Boni, Rachel W. Humphrey, Aung Naing · 2019 · Clinical Cancer Research
33. Mechanisms of immune escape in the cancer immune cycle
    Sha Tang, Qian Ning, Ling Yang, Zhongcheng Mo, Shengsong Tang · 2020 · International Immunopharmacology
34. Insulin-Like Growth Factor (IGF) Pathway Targeting in Cancer: Role of the IGF Axis and Opportunities for Future Combination Studies
    Aaron D. Simpson, Wilfride V. Petnga Kamdoum, Valentine M. Macaulay, Ulrike Weyer-Czernilofsky, Thomas Bogenrieder · 2017 · Targeted Oncology
35. HDAC inhibition potentiates immunotherapy in triple negative breast cancer
    Terranova-Barberio, Manuela, Thomas, Scott, Ali, Niwa, Pawlowska, Nela, Park, Jeenah, Krings, Gregor, Rosenblum, Michael D., Budillon, Alfredo, Munster, Pamela N. · 2017 · Oncotarget
36. Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis
    Sarah E. Chuzi, Fabio Rocha Fernandes Tavora, Marcelo Rocha de Souza Cruz, Ricardo Lima Barros Costa, Young Kwang Chae, Benedito A. Carneiro, Francis Joseph Giles · 2017 · Cancer Management and Research
37. Intratumoral STING Activation with T-cell Checkpoint Modulation Generates Systemic Antitumor Immunity
    Casey R. Ager, Matthew J. Reilley, Courtney Nicholas, Todd Bartkowiak, Ashvin R. Jaiswal, Michael A. Curran · 2017 · Cancer Immunology Research
38. Inflammatory eruptions associated with immune checkpoint inhibitor therapy: A single-institution retrospective analysis with stratification of reactions by toxicity and implications for management
    Emily L. Coleman, Christine J. Ko, Feng Dai, Mary M. Tomayko, Harriet M. Kluger, Jonathan Scott Leventhal · 2018 · Journal of the American Academy of Dermatology
39. Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab
    Martens, Alexander, Wistuba-Hamprecht, Kilian, Yuan, Jianda, Postow, Michael A., Wong, Phillip, Capone, Mariaelena, Madonna, Gabriele, Khammari, Amir, Schilling, Bastian, Sucker, Antje et al. · 2016 · Clinical Cancer Research
40. Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors
    Lidar, Merav, Giat, Eitan, Garelick, Daniela, Horowitz, Yuval, Amital, Howard, Steinberg-Silman, Yael, Schachter, Jacob, Shapira-Frommer, Ronnie, Markel, Gal · 2018 · Autoimmunity Reviews
41. Current issues and perspectives in PD-1 blockade cancer immunotherapy
    Kenji Chamoto, Ryusuke Hatae, Tasuku Honjo · 2020 · International Journal of Clinical Oncology
42. Assessment of programmed death-ligand 1 expression and tumor-associated immune cells in pediatric cancer tissues
    Majzner, Robbie G., Simon, Jason S., Grosso, Joseph F., Martinez, Daniel, Pawel, Bruce R., Santi, Mariarita, Merchant, Melinda S., Geoerger, Birgit, Hezam, Imene, Marty, Virginie et al. · 2017 · Cancer
43. Gut microbiome modulates efficacy of immune checkpoint inhibitors
    Yi, Ming, Yu, Shengnan, Qin, Shuang, Liu, Qian, Xu, Hanxiao, Zhao, Weiheng, Chu, Qian, Wu, Kongming · 2018 · Journal of Hematology & Oncology
44. Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience
    Takeo Fujii, Rivka R. Colen, Mehmet Asım Bilen, Kenneth R. Hess, Joud Hajjar, Maria Eugenia Suarez-Almazor, Anas Alshawa, David S. Hong, Apostolia Maria Tsimberidou, Filip Jankú et al. · 2017 · Investigational New Drugs
45. Multispectral imaging for quantitative and compartment‐specific immune infiltrates reveals distinct immune profiles that classify lung cancer patients
    Artur Mezheyeuski, Christian Holst Bergsland, Max Backman, Dijana Djureinovic, Tobias Sjöblom, Jarle Bruun, Patrick Micke · 2017 · The Journal of Pathology
46. VISTA is highly expressed on MDSCs and mediates an inhibition of T cell response in patients with AML
    Liru Wang, Bei Jia, David F. Claxton, William Christopher Ehmann, Witold B. Rybka, Shin Mineishi, Seema G Naik, Muhammad Rizwan Khawaja, Jeff Sivik, Junyan Han et al. · 2018 · OncoImmunology
47. Multiplex Quantitative Analysis of Tumor-Infiltrating Lymphocytes and Immunotherapy Outcome in Metastatic Melanoma
    Pok Fai Wong, Wei Wei, James William Smithy, Balázs Ács, Maria I Toki, Kim Blenman, Daniel A. Zelterman, Harriet M. Kluger, David L. Rimm · 2019 · Clinical Cancer Research
48. Model of Patient-Specific Immune-Enhanced Organoids for Immunotherapy Screening: Feasibility Study
    Konstantinos Ioannis Votanopoulos, Steven Donald Forsythe, Hemamylammal Sivakumar, Andrea R. Mazzocchi, Julio Aleman, Lance David Miller, Edward Allen Levine, Pierre L. Triozzi, Aleksander Skardal · 2019 · Annals of Surgical Oncology
49. Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)
    Michael J Wagner, Megan K. D. Othus, Sandip Pravin Patel, Chris Ryan, Ashish Sangal, Benjamin Powers, George Thomas Budd, Adrienne I. Victor, Chung-Tsen Hsueh, Rashmi K Chugh et al. · 2021 · Journal for ImmunoTherapy of Cancer
50. Inhibition of the CCL2 receptor, CCR2, enhances tumor response to immune checkpoint therapy
    Megan M. Tu, Hany A. Abdel-Hafiz, Robert T. Jones, Annie Jean, Katelyn J. Hoff, Jason E. Duex, Ana Chauca-Diaz, James C. Costello, Garrett Marc Dancik, Beth A. Jirón Tamburini et al. · 2020 · Communications Biology
51. CD8+ T cells and NK cells: parallel and complementary soldiers of immunotherapy
    Jillian N. Rosenberg, Jun Huang · 2017 · Current Opinion in Chemical Engineering
52. Updates on immunotherapy for colorectal cancer
    Aparna Kalyan, Sheetal Mehta Kircher, Hiral Anil Shah, Mary F. Mulcahy, Al B. Benson · 2018 · Journal of Gastrointestinal Oncology
53. Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial
    Paolo A. Ascierto, Evan J. Lipson, Reinhard Dummer, James Larkin, Georgina Venetia Long, Rachel E. Sanborn, Vanna Chiarion‐Sileni, Brigitte Dréno, Stéphane Dalle, Dirk Schadendorf et al. · 2023 · Journal of Clinical Oncology
54. Endocrine side effects of cancer immunotherapy
    Cukier, Priscilla, Santini, Fernando C, Scaranti, Mariana, Hoff, Ana O · 2017 · Endocrine-Related Cancer
55. Genomic Approaches to Understanding Response and Resistance to Immunotherapy
    David A. Braun, Kelly P. Burke, Eliezer M. Van Allen · 2016 · Clinical Cancer Research
56. Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives
    Lidia Yshii, Reinhard Hohlfeld, Roland Liblau · 2017 · Nature Reviews Neurology
57. Emerging Nano‐/Microapproaches for Cancer Immunotherapy
    Yu Mi, C. Tilden Hagan, Benjamin Garrett Vincent, Andrew Zhuang Wang · 2019 · Advanced Science
58. Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO+IPI: a systematic review and meta-analysis
    Puyuan Xing, Fan Zhang, Guoqiang Wang, Yu Xu, Chengcheng Li, Shouzheng Wang, Yiying Guo, Shangli Cai, Yan Wang, Junling Li · 2019 · Journal for ImmunoTherapy of Cancer
59. The immune mechanisms of abscopal effect in radiation therapy
    George Daniel Grass, Niveditha Krishna, Sungjune Kim · 2015 · Current Problems in Cancer
60. Immunotherapy and Novel Combinations in Oncology: Current Landscape, Challenges, and Opportunities
    KM Morrissey, Theresa M. Yuraszeck, Chi‐Chung Li, Y Zhang, Sreeneeranj Kasichayanula · 2016 · Clinical and Translational Science
61. The role of neoantigens in response to immune checkpoint blockade
    Nadeem Riaz, Luc G.T. Morris, Jonathan J. Havel, Vladimir Makarov, Alexis Desrichard, Timothy An-thy Chan · 2016 · International Immunology
62. A framework for understanding and targeting residual disease in oncogene-driven solid cancers
    Trever Grant Bivona, Robert Charles Doebele · 2016 · Nature Medicine
63. Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression
    Georgina Venetia Long, Jeffrey S. Weber, James Larkin, Victoria G. Atkinson, Jean‐Jacques Grob, Dirk Schadendorf, Reinhard Dummer, Caroline Robert, Iván Márquez‐Rodas, Catriona M. McNeil et al. · 2017 · JAMA Oncology
64. NRAS-mutant melanoma: current challenges and future prospect
    Eva Muñoz‐Couselo, Esther Zamora, Carolina Ortiz, Jesús Soberino-García, José Manuel Pérez-García · 2017 · OncoTargets and Therapy
65. Synthetic immune niches for cancer immunotherapy
    Jorieke Weiden, Jurjen Tel, Carl Gustav Figdor · 2017 · Nature reviews. Immunology
66. Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)
    Jeffrey S. Weber, Dirk Schadendorf, Michele Del Vecchio, James Larkin, Victoria G. Atkinson, Michael Schenker, Jacopo Pigozzo, Helen J Gogas, Stéphane Dalle, Nicolás Meyer et al. · 2022 · Journal of Clinical Oncology
67. The role of tumor-infiltrating lymphocytes (TILs) as a predictive biomarker of response to anti-PD1 therapy in patients with metastatic non-small cell lung cancer or metastatic melanoma
    Anton Uryvaev, Maria Passhak, Dov Hershkovits, Edmond Sabo, Gil Bar‐Sela · 2018 · Medical Oncology
68. Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options
    Derya Kabacaoğlu, Katrin J. Ciecielski, Dietrich Alexander Ruess, Hana Algül · 2018 · Frontiers in Immunology
69. Development of immune checkpoint therapy for cancer
    Jill M. Fritz, Michael J. Lenardo · 2019 · The Journal of Experimental Medicine
70. Survival of patients with advanced metastatic melanoma: The impact of novel therapies
    Selma Ugurel, Joachim Röhmel, Paolo A. Ascierto, Keith T. Flaherty, Jean‐Jacques Grob, Axel Hauschild, James Larkin, Georgina Venetia Long, Paul C. Lorigan, Grant A. McArthur et al. · 2015 · European Journal of Cancer
71. PSGL-1 Is an Immune Checkpoint Regulator that Promotes T Cell Exhaustion
    Roberto Tinoco, Florent Carrette, Monique L. Henriquez, Dennis C. Otero, Jonathan Magaña, Marcus Bosenberg, Susan L. Swain, Linda M. Bradley · 2016 · Immunity
72. Future perspectives in melanoma research
    Paolo A. Ascierto, Sanjiv S. Agarwala, Gerardo Botti, Alessandra Cesano, Gennaro Ciliberto, Michael A. Davies, Sandra Demaria, Reinhard Dummer, Alexander M.M. Eggermont, Soldano Ferrone et al. · 2016 · Journal of Translational Medicine
73. Management of patients with recurrent/advanced cervical cancer beyond first line platinum regimens: Where do we stand? A literature review
    Stergios Boussios, Esmeralda Seraj, George Zarkavelis, Dimitrios Petrakis, Aristomenes Kollas, Aikaterini Kafantari, Avraam Assi, Konstantina Tatsi, Nicholas A. Pavlidis, George E. Pentheroudakis · 2016 · Critical Reviews in Oncology/Hematology
74. Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
    Laurence P. Diggs, Eddy C. Hsueh · 2017 · Biomarker Research
75. Chemical Strategies to Boost Cancer Vaccines
    Wenhao Li, Yanmei Li · 2020 · Chemical Reviews
76. The Abscopal Effect: A Review of Pre-Clinical and Clinical Advances
    James Robert Janopaul-Naylor, Yang Shen, David C. Qian, Zachary S. Buchwald · 2021 · International Journal of Molecular Sciences
77. Multivalent bi-specific nanobioconjugate engager for targeted cancer immunotherapy
    Hengfeng Yuan, Wen Jiang, Christina A. Von Roemeling, Yaqing Qie, Xiujie Liu, Yuanxin Chen, Yifan Wang, Robert E. Wharen, Kyuson Yun, Guojun Bu et al. · 2017 · Nature Nanotechnology
78. Understanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade
    Amy L. Shergold, Rhona Millar, Robert J. B. Nibbs · 2019 · Pharmacological Research
79. Immune Checkpoint Inhibitors in 10 Years: Contribution of Basic Research and Clinical Application in Cancer Immunotherapy
    Jii Bum Lee, Hye Ryun Kim, Sang‐Jun Ha · 2022 · Immune Network
80. Combined VEGF and PD-L1 Blockade Displays Synergistic Treatment Effects in an Autochthonous Mouse Model of Small Cell Lung Cancer
    Lydia Meder, Philipp Schuldt, Martin Thelen, Anna Schmitt, Felix Dietlein, Sebastian Klein, Sven Borchmann, Kerstin Wennhold, Ignacija Vlašić, Sebastian Oberbeck et al. · 2018 · Cancer Research
81. The risk of cardiac events in patients receiving immune checkpoint inhibitors: a nationwide Danish study
    Maria D’Souza, Dorte Lisbet Nielsen, Inge Marie Svane, Kasper Karmark Iversen, Peter Vibe Rasmussen, Christian Madelaire, Emil Loldrup Fosbøl, Lars Køber, Finn Gustafsson, Charlotte Andersson et al. · 2020 · European Heart Journal
82. Signaling pathways and targeted therapies in lung squamous cell carcinoma: mechanisms and clinical trials
    Zhenyi Niu, Runsen Jin, Yan Zhang, Hecheng Li · 2022 · Signal Transduction and Targeted Therapy
83. Anti-TGF-β/PD-L1 bispecific antibody promotes T cell infiltration and exhibits enhanced antitumor activity in triple-negative breast cancer
    Ming Yi, Yuze Wu, Mengke Niu, Shuangli Zhu, Jing Zhang, Yongxiang Yan, Pengfei Zhou, Zhijun Dai, Kongming Wu · 2022 · Journal for ImmunoTherapy of Cancer
84. Prognostic impact of CD73 and A2A adenosine receptor expression in non-small-cell lung cancer
    Yusuke Inoue, Katsuhiro Yoshimura, Nobuya Kurabe, Tomoaki Kahyo, Akikazu Kawase, Masayuki Tanahashi, Hiroshi Ogawa, Naoki Inui, Kazuhito Funai, Kazuya Shinmura et al. · 2017 · Oncotarget
85. Hepatocellular Carcinoma Cells Up-regulate PVRL1, Stabilizing PVR and Inhibiting the Cytotoxic T-Cell Response via TIGIT to Mediate Tumor Resistance to PD1 Inhibitors in Mice
    David Kung‐Chun Chiu, Vincent Wai‐Hin Yuen, Jacinth Wing‐Sum Cheu, Larry Lai Wei, Vox Ting, Michael Fehlings, Hermi Sumatoh, Alessandra Nardin, Evan William Newell, Irene Oi‐Lin Ng et al. · 2020 · Gastroenterology
86. Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: a case series
    Kim, Sang Taek, Tayar, Jean, Trinh, Van Anh, Suarez-Almazor, Maria, Garcia, Salvador, Hwu, Patrick, Johnson, Daniel Hartman, Uemura, Marc, Diab, Adi · 2017 · Annals of the Rheumatic Diseases
87. Diagnosis and Treatment of Kaposi Sarcoma
    Johann W. Schneider, Dirk P. Dittmer · 2017 · American Journal of Clinical Dermatology
88. Targets for immunotherapy of liver cancer
    Tim F. Greten, Bruno Sangro · 2017 · Journal of Hepatology
89. Checkpoint Blockade Toxicity and Immune Homeostasis in the Gastrointestinal Tract
    Michael Lawrence Dougan · 2017 · Frontiers in Immunology
90. Impaired B‐cell tolerance checkpoints promote the development of autoimmune diseases and pathogenic autoantibodies
    Eric Meffre, Kevin C. O’Connor · 2019 · Immunological Reviews
91. The treatment of advanced melanoma: Current approaches and new challenges
    Andrea Boutros, Elena Croce, Marco Ferrari, Riccardo Gili, Giulia Massaro, Riccardo Marconcini, Luca Arecco, Enrica T. Tanda, Francesco Spagnolo · 2024 · Critical Reviews in Oncology/Hematology
92. Dual Targeting Nanoparticle Stimulates the Immune System To Inhibit Tumor Growth
    Alyssa K. Kosmides, John-William Sidhom, Andrew K. Fraser, Catherine Ami Bessell, Jonathan P. Schneck · 2017 · ACS Nano
93. Advances in Cancer Immunotherapy in Solid Tumors
    Smitha Patiyil Menon, Sarah J. Shin, Grace Kho Dy · 2016 · Cancers
94. TriMix and tumor antigen mRNA electroporated dendritic cell vaccination plus ipilimumab: link between T-cell activation and clinical responses in advanced melanoma
    Brenda De Keersmaecker, Sofie Claerhout, Javier Carrasco, Isabelle Bar, Jurgen Corthals, Sofie Wilgenhof, Bart Neyns, Kris Thielemans · 2020 · Journal for ImmunoTherapy of Cancer
95. Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy
    John B.A.G. Haanen, Marc S. Ernstoff, Yinghong Wang, Alexander Maxwell Menzies, Igor J. Puzanov, Petros D. Grivas, James Larkin, Solange Peters, John A. Thompson, Michel Obéid · 2020 · Journal for ImmunoTherapy of Cancer
96. Gastrointestinal and Hepatic Complications of Immune Checkpoint Inhibitors
    Cramer, Peyton, Bresalier, Robert S. · 2017 · Current Gastroenterology Reports
97. Correlation of B7-H3 with androgen receptor, immune pathways and poor outcome in prostate cancer: an expression-based analysis
    Benjamin Benzon, Shuang George Zhao, Michael C. Haffner, Mandeep M. Takhar, Nicholas Erho, Kasra Yousefi, Paula J. Hurley, Jennifer L. Bishop, Jeffrey J. Tosoian, Kamyar Ghabili et al. · 2016 · Prostate Cancer and Prostatic Diseases
98. Intratumoral CD8+ T-cell Apoptosis Is a Major Component of T-cell Dysfunction and Impedes Antitumor Immunity
    Brendan L. Horton, Jason B. Williams, Alexandra Cabanov, Stefani Spranger, Thomas Frank Gajewski · 2017 · Cancer Immunology Research
99. Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysis
    Julia A. Beaver, Maitreyee Hazarika, Flora A. Mulkey, Sirisha L. Mushti, Huanyu Chen, Kun He, Rajeshwari Sridhara, Kirsten B. Goldberg, Meredith Kathleen Chuk, Dow-Chung Chi et al. · 2018 · The Lancet Oncology
100. B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity
     Kimio Yonesaka, Koji Haratani, Shiki Takamura, Hitomi Sakai, Ryoji Kato, Naoki Takegawa, Takayuki Takahama, Kaoru Tanaka, Hidetoshi Hayashi, Masayuki Takeda et al. · 2018 · Clinical Cancer Research